Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00263575

Recruitment Status : Completed

First Posted : December 9, 2005

Last Update Posted : February 1, 2013

Sponsor:

Information provided by (Responsible Party):

Prostrakan Pharmaceuticals

Study Description

Brief Summary:

The purpose of this study is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid cancer patients who are using stable doses of opioid medication.

Condition or disease	Intervention/treatment	Phase
Pain Cancer	Drug: EN3267	Phase 3

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	97 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakthrough Pain in Cancer Patients
Study Start Date :	January 2005
Actual Primary Completion Date :	December 2008
Actual Study Completion Date :	February 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Fentanyl Fentanyl citrate

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: sublingual fentanyl tablet	Drug: EN3267 EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses

Outcome Measures

Primary Outcome Measures :

The Study Objective is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid tolerant cancer patients who are using stable doses of opioid medication. [ Time Frame: screening and monthly study visits ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	17 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males or females 17 years of age or older.
Stable cancer-related pain.
Are receiving a stable, fixed-schedule oral opioid regimen equivalent to 60 to 1000 mg of oral morphine per day or transdermal fentanyl therapy equivalent to 50 to 300 µg/h, and are on a stable dose of opioid medication for relief of breakthrough pain.
Experiencing 1-4 episodes of breakthrough pain per day.
Meet the criteria defined in the Eastern Cooperative Oncology Group (ECOG) Performance Status for Grade 0, 1, or 2.

Exclusion Criteria:

Have previously been exposed to EN3267.
Are pregnant or lactating.
Have uncontrolled or rapidly escalating pain.
Have any clinically significant condition that would, in the investigator's opinion, preclude participation in the study or compromise data collection. These conditions may include cardiopulmonary disease, and/or neurologic/psychologic conditions.
Are scheduled to take MAOIs (monoamine oxidase inhibitors) during the study.
Are scheduled to receive anti-neoplastic therapy that, in the investigator's opinion, will influence assessment of breakthrough pain.
Are scheduled to receive an investigational drug other than EN3267 during the course of the study.
Have hypersensitivity, allergy or contraindication to fentanyl.
Have significant prior history of substance abuse or alcohol abuse.
Would have difficulty complying with the protocol, as assessed by the investigator.
Are unable to read, write, or comprehend the English language in order to complete diaries.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00263575

Locations


United States, North Carolina
Carolinas Pain Institute
Winston-Salem, North Carolina, United States, 27103

Sponsors and Collaborators

Prostrakan Pharmaceuticals

Investigators


Study Director:	Julian Howell	Prostrakan Pharmaceuticals

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Nalamachu S, Hassman D, Wallace MS, Dumble S, Derrick R, Howell J. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin. 2011 Mar;27(3):519-30. doi: 10.1185/03007995.2010.545380. Epub 2011 Jan 6.


Responsible Party:	Prostrakan Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00263575 History of Changes
Other Study ID Numbers:	EN3267-007
First Posted:	December 9, 2005 Key Record Dates
Last Update Posted:	February 1, 2013
Last Verified:	January 2013

Keywords provided by Prostrakan Pharmaceuticals:


EN3267 Breakthrough Pain Safety Study Fentanyl Tablets

Additional relevant MeSH terms:


Breakthrough Pain Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Fentanyl Analgesics, Opioid Narcotics Central Nervous System Depressants	Physiological Effects of Drugs Analgesics Sensory System Agents Peripheral Nervous System Agents Adjuvants, Anesthesia Anesthetics, Intravenous Anesthetics, General Anesthetics

To Top